Pneumonia: a common threat
with serious consequences

A leading cause of
infection-related death in the US1

The need for new antibiotics

~5 mm pneumonia cases annually

~5 mm

~5 mm pneumonia cases annually—

and incidence is expected to rise2,3

S. pneumoniae causes about 36% of all pneumonia cases classified as CABP

S. pneumoniae causes about 36% of all
pneumonia cases classified as CABP4

60% of pneumonia cases are treated in the hospital

Driving up hospitalizations

60% of pneumonia cases are treated in the hospital5

New antibiotics are valuable to effective antibiotic stewardship

For nearly 20 years, there has been no novel class approved for the treatment of CABP—yet new antibiotics are valuable for effective antibiotic stewardship6-8

IDSA/SHEA antibiotic stewardship guidelines for antibiotic use and sustainability include but are not limited to6,9:

Transitioning early from IV to oral

Transitioning early
from IV to oral

administration to help shorten length of stay

shortest effective duration

Using antibiotic therapy for the

shortest
effective duration

new antibiotic classes

Developing systemic drugs in

new antibiotic classes

to address resistance

IDSA=Infectious Diseases Society of America; SHEA=Society of Healthcare Epidemiology in America.
CABP is a designation by the FDA to refer specifically to CAP patients with bacterial pneumonia.